On September 15, 2016 argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, reported that it will host its inaugural R&D day on Thursday, September 22, 2016 from 9:00 a.m. -12:00 p.m. ET in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the event, members of argenx management will present updates to the Company’s pipeline of differentiated antibodies including ARGX-113 for severe autoimmune diseases and ARGX-110 for oncology indications.

Guest speakers will also present on the treatment landscape and unmet needs in selected argenx indications including;

James Howard, Jr., M.D., Chief, Neuromuscular Disorders Section, University of North Carolina, Chapel Hill, North Carolina, USA
Adrian Newland, M.D., Professor of Hematology, The Royal London Hospital, London, UK
Owen O’Connor, MD, PhD, Director of the Center for Lymphoid Malignancies, Colombia University, New York, USA